0
Royalty Pharma plc Banner Image

Royalty Pharma plc

  • Ticker RPRX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Royalty Pharma plc Logo Image
  • 11-50 Employees
  • Based in New York City, New York
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio ofMore royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 11 development-stage product candidates.
REPORT RATINGS
5.0 / 5.0 (1)

Royalty Pharma plc reports have an aggregate usefulness score of 5.0 based on 1 reviews.

Royalty Pharma plc

Most Recent Annual Report

Royalty Pharma plc
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Royalty Pharma plc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!